- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Zoledronic Acid Teva Generics has been withdrawn at the request of the marketing-authorisation holder.
Zoledronic acid Teva Generics : EPAR - Summary for the public
English (EN) (541.61 KB - PDF)
български (BG) (627.31 KB - PDF)
español (ES) (564.04 KB - PDF)
čeština (CS) (604.81 KB - PDF)
dansk (DA) (542.77 KB - PDF)
Deutsch (DE) (543.14 KB - PDF)
eesti keel (ET) (540.92 KB - PDF)
ελληνικά (EL) (643.63 KB - PDF)
français (FR) (543.03 KB - PDF)
hrvatski (HR) (562.2 KB - PDF)
italiano (IT) (539.95 KB - PDF)
latviešu valoda (LV) (621.43 KB - PDF)
lietuvių kalba (LT) (565.97 KB - PDF)
magyar (HU) (599.83 KB - PDF)
Malti (MT) (603.28 KB - PDF)
Nederlands (NL) (541.26 KB - PDF)
polski (PL) (605.31 KB - PDF)
português (PT) (543.04 KB - PDF)
română (RO) (566.14 KB - PDF)
slovenčina (SK) (604.86 KB - PDF)
slovenščina (SL) (596.41 KB - PDF)
Suomi (FI) (539.97 KB - PDF)
svenska (SV) (540.78 KB - PDF)
Zoledronic acid Teva Generics : EPAR - Risk-management-plan summary
English (EN) (538.9 KB - PDF)
Product information
Zoledronic acid Teva Generics : EPAR - Product Information
English (EN) (1.12 MB - PDF)
български (BG) (2.6 MB - PDF)
español (ES) (1.14 MB - PDF)
čeština (CS) (2.09 MB - PDF)
dansk (DA) (1.11 MB - PDF)
Deutsch (DE) (1.22 MB - PDF)
eesti keel (ET) (1.16 MB - PDF)
ελληνικά (EL) (2.67 MB - PDF)
français (FR) (1.13 MB - PDF)
hrvatski (HR) (1.22 MB - PDF)
íslenska (IS) (1.18 MB - PDF)
italiano (IT) (1.19 MB - PDF)
latviešu valoda (LV) (2.21 MB - PDF)
lietuvių kalba (LT) (1.31 MB - PDF)
magyar (HU) (2.15 MB - PDF)
Malti (MT) (2.2 MB - PDF)
Nederlands (NL) (1.02 MB - PDF)
norsk (NO) (1.09 MB - PDF)
polski (PL) (2.2 MB - PDF)
português (PT) (1.15 MB - PDF)
română (RO) (1.29 MB - PDF)
slovenčina (SK) (2.17 MB - PDF)
slovenščina (SL) (2.23 MB - PDF)
Suomi (FI) (1.11 MB - PDF)
svenska (SV) (1.07 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zoledronic acid Teva Generics : EPAR - All Authorised presentations
English (EN) (480.97 KB - PDF)
български (BG) (527.49 KB - PDF)
español (ES) (476.03 KB - PDF)
čeština (CS) (513.46 KB - PDF)
dansk (DA) (491.94 KB - PDF)
Deutsch (DE) (491.48 KB - PDF)
eesti keel (ET) (481.5 KB - PDF)
ελληνικά (EL) (520.56 KB - PDF)
français (FR) (481.64 KB - PDF)
hrvatski (HR) (497.75 KB - PDF)
íslenska (IS) (481.94 KB - PDF)
italiano (IT) (481.73 KB - PDF)
latviešu valoda (LV) (514.58 KB - PDF)
lietuvių kalba (LT) (499.05 KB - PDF)
magyar (HU) (513.73 KB - PDF)
Malti (MT) (512.19 KB - PDF)
Nederlands (NL) (482.01 KB - PDF)
norsk (NO) (481.54 KB - PDF)
polski (PL) (509.61 KB - PDF)
português (PT) (479.73 KB - PDF)
română (RO) (494.58 KB - PDF)
slovenčina (SK) (504.57 KB - PDF)
slovenščina (SL) (503.36 KB - PDF)
Suomi (FI) (470.36 KB - PDF)
svenska (SV) (476.21 KB - PDF)
Product details
- Name of medicine
- Zoledronic acid Teva Generics
- Active substance
- zoledronic acid monohydrate
- International non-proprietary name (INN) or common name
- zoledronic acid
- Therapeutic area (MeSH)
- Osteoporosis
- Osteitis Deformans
- Anatomical therapeutic chemical (ATC) code
- M05BA08
Pharmacotherapeutic group
BisphosphonatesTherapeutic indication
Treatment of osteoporosis
- in post-menopausal women
- in adult men
at increased risk of fracture, including those with recent low-trauma hip fracture.
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
- in post-menopausal women
- in adult men
at increased risk of fracture.
Treatment of Paget's disease of the bone in adults.
Authorisation details
- EMA product number
- EMEA/H/C/002805
Generic
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
- Marketing authorisation holder
- Teva Generics B.V
Computerweg 10
Postbus 43028
3540AA Utrecht
The Netherlands - Opinion adopted
- 23/01/2014
- Marketing authorisation issued
- 27/03/2014
- Revision
- 2
Assessment history
Zoledronic acid Teva Generics : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (533.21 KB - PDF)
Zoledronic acid Teva Generics : EPAR - Public assessment report
English (EN) (773.29 KB - PDF)
CHMP summary of positive opinion for Zoledronic acid Teva Generics
English (EN) (66.7 KB - PDF)
News on Zoledronic acid Teva Generics
More information on Zoledronic acid Teva Generics
Public statement on Zoledronic acid Teva Generics: Withdrawal of the marketing authorisation in the European Union
English (EN) (66.2 KB - PDF)